Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

FOR IMMEDIATE RELEASE

Luma Therapeutics Raises $2M Round A and Announces Addition of Matthew E. Likens, Former CEO of Ulthera to Board

MILLBRAE, CA – February 21, 2017 – Luma Therapeutics, Inc., a medical device company developing innovative technologies for inflammatory skin disease, announced today that it has raised $2 million in private financing with new and existing investors. The company will use the proceeds to continue collecting clinical evidence supporting its flagship product, the Luma Light System™, and preparing the system for commercial release.

In other news, Luma announced that Matt Likens, has joined its Board of Directors. Mr. Likens is a principal at Likens Healthcare and Management Consulting, LLC. He was the President and CEO of Ulthera, Inc. from 2006 to 2016. Prior to Ulthera, Mr. Likens was employed at GMP Companies, Inc. as President of GMP Wireless Medicine from 2001 to 2006 and Executive Vice President, Operations from 2001 to 2004. Mr. Likens previously served in various capacities at Baxter Healthcare Corporation from 1978 to 2001, and was President of Baxter’s Renal U.S. business upon his departure in January, 2001.

The Luma Light System consists of the Luma Light and Luma Patch. The Luma Light is an array of ultraviolet-B light-emitting diodes (LEDs) that connect to an app on a patient’s phone to control and monitor the applied dose, based on a doctor’s prescription. The Luma Patch is a patented occlusive hydrogel dressing designed to increase skin hydration and reduce inflammation.

Luma Therapeutics has conducted two small pilot studies and recently started a multi-center randomized study to demonstrate the safety and efficacy of the Luma Light System in treating psoriasis, one of the most prevalent inflammatory skin diseases, in patients’ homes. The company plans to submit the system to the U.S. Food and Drug Administration for regulatory clearance this year.

Matt Likens stated, “I was impressed by the early clinical data and by the team’s commitment to helping people with inflammatory skin disease. I am thrilled to join the board and provide guidance as the company moves towards commercialization.”

“We started Luma Therapeutics to empower people suffering from inflammatory skin disease by putting light-based therapy in their hands,” said Evan Anderson, Founder and CEO of Luma Therapeutics. “The addition of Matt to our board and raising our Series A financing validates our vision and takes us another step towards helping people with the Luma Light System™.”

About Luma Therapeutics: Luma Therapeutics, Inc. is a medical device company based in Millbrae, CA. Founded in 2013, Luma Therapeutics is developing light therapy systems to improve inflammatory skin disease, starting with psoriasis.

Luma Therapeutics (www.lumatherapeutics.com)

10 Rollins Rd, Suite 120, Millbrae, CA 94030

650-260-8245 – info@lumatherapeutics.com

 

 

###

Author: Evan Anderson

Evan has 15 years of experience developing early stage medical devices product and markets at both large companies and startups. He was the 5th employee and R&D manager at Spiracur (acquired by Acelity) and led the development of their first commercial negative pressure wound care therapy, called SNaP™. He was also Spiracur’s 5th territory manager and spent two years managing distribution sales. Evan holds a BS in Biomedical Engineering from Johns Hopkins University as well as a Master’s in Biomedical Engineering from Case Western Reserve University.

Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn